Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMYLT67)

Drug Name
TKI258 Drug Info
Synonyms
Dovitinib; 405169-16-6; CHIR-258; TKI-258; Chir 258; 4-Amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; CHIR258; Dovitinib (TKI-258, CHIR-258); UNII-I35H55G906; CHEMBL522892; 804551-71-1; I35H55G906; TKI 258; 1027263-12-2; (3Z)-4-Amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1,3-dihydro-2H-benzimidazol-2-ylidene]-2(3H)-quinolinone; C21H21FN6O; 4-Amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
Therapeutic ClassAnticancer Agents
Cross-matching ID
PubChem CID
135611162
CAS Number
CAS 915769-50-5
TTD Drug ID
D07OZR
INTEDE Drug ID
DR1815

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Glycine, serine and threonine metabolism 2.05 9.42e-3 31/40 (77.5%) PSAT1;PHGDH;CBS;...
Cysteine and methionine metabolism 1.94 9.42e-3 43/50 (86%) PSAT1;PHGDH;CBS;...
Graft-versus-host disease 1.94 6.28e-3 32/42 (76.19%) FAS;CD86;HLA-DQB1;...
Cytosolic DNA-sensing pathway 1.87 7.07e-3 52/63 (82.54%) CXCL10;CCL4;NFKBIA;...
Allograft rejection 1.87 9.42e-3 32/38 (84.21%) CD40;FAS;CD86;...
Alanine, aspartate and glutamate metabolism 1.85 1.26e-2 27/37 (72.97%) ASNS;ASS1;GOT1;...
Intestinal immune network for IgA production 1.82 2.02e-2 38/48 (79.17%) CD40;CD86;HLA-DQB1;...
Asthma 1.76 3.42e-2 25/31 (80.65%) CD40;HLA-DQB1;FCER1A;...
Viral protein interaction with cytokine and cytokine re... 1.76 3.04e-2 84/100 (84%) CXCL10;TNFRSF10B;CXCL9;...
Transcriptional misregulation in cancer 1.75 2.92e-2 158/192 (82.29%) ARNT2;CDKN1A;CCND2;...
Inflammatory bowel disease 1.73 3.17e-2 58/65 (89.23%) STAT1;HLA-DQB1;HLA-DOB;...
Staphylococcus aureus infection 1.70 3.85e-2 72/95 (75.79%) FPR1;CFB;ICAM1;...
Influenza A 1.67 4.86e-2 156/172 (90.7%) CXCL10;TNFRSF10B;STAT1;...
p53 signaling pathway 1.67 4.58e-2 63/73 (86.3%) CDKN1A;CCND2;TNFRSF10B;...
ECM-receptor interaction -1.83 4.84e-2 80/88 (90.91%) TNXB;COL4A6;ITGB6;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone marrow
Chronic myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
K-562 CVCL_0004 Homo sapiens 0.01uM - 10uM 4H, 24H
Multiple myeloma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
KMS-34 CVCL_1333 Homo sapiens 0.01uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
SK-BR-3 CVCL_0033 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
Breast carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BT-20 CVCL_0178 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
Hs 578T CVCL_0332 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
Fibrocystic breast disease
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A (Parent) CVCL_0598 Homo sapiens 1.11uM - 10uM 3H, 6H, 12H, 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.04uM - 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.04uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
1HAEo- CVCL_0128 Homo sapiens 10uM 24H
NL20 CVCL_0461 Homo sapiens 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.04uM - 10uM 6H, 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.04uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 0.04uM - 10uM 6H, 24H
Normal (Fibroblast)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HFL1 CVCL_4295 Homo sapiens 10uM 24H
IMR-90 CVCL_0347 Homo sapiens 10uM 24H
WI-38 CVCL_0579 Homo sapiens 10uM 24H
Lymph node
Burkitt lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BJAB CVCL_5711 Homo sapiens 0.01uM - 10uM 4H
Diffuse large B-cell lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HBL-1 CVCL_4213 Homo sapiens 0.01uM - 10uM 4H, 24H
OCI-Ly10 CVCL_8795 Homo sapiens 0.01uM - 10uM 24H
OCI-Ly19 CVCL_8797 Homo sapiens 0.01uM - 10uM 4H, 24H
OCI-Ly3 CVCL_8796 Homo sapiens 0.01uM - 10uM 4H, 24H
TMD8 CVCL_A440 Homo sapiens 0.01uM - 10uM 4H, 24H
Peripheral blood
Acute B-lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NALM-6 CVCL_0092 Homo sapiens 0.01uM - 10uM 24H
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 4H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.04uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.04uM - 10uM 6H, 24H
SK-MEL-5 CVCL_0527 Homo sapiens 0.01uM - 10uM 24H